Transcatheter aortic valve implantation in a patient with previous Starr-Edwards mitral valve prosthesis

Heart ◽  
2012 ◽  
Vol 99 (3) ◽  
pp. 217-218 ◽  
Author(s):  
Mohammed Shamim Rahman ◽  
David Roy ◽  
Stephen J Brecker
Keyword(s):  
Mitral Valve ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Valve Prosthesis ◽  
Transcatheter Aortic Valve ◽  
Mitral Valve Prosthesis ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI)

2015 ◽  
Vol 113 (04) ◽  
pp. 674-685 ◽  
Author(s):  
Vincent J. Nijenhuis ◽  
Naoual Bennaghmouch ◽  
Jan-Peter van Kuijk ◽  
Davide Capodanno ◽  
Jurriën M. ten Berg
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Bleeding Complications ◽  
Valve Prosthesis ◽  
Surgical Aortic Valve Replacement ◽  
Transcatheter Aortic Valve ◽  
Mitral Valve Prosthesis ◽  
Ischemic Complications ◽  
Aortic Valve Implantation ◽  
Valve Implantation

SummaryTranscatheter aortic valve implantation (TAVI) is an established treatment option for symptomatic patients with severe aortic valvular disease who are not suitable for conventional surgical aortic valve replacement. Despite improving experience and techniques, ischaemic and bleeding complications after TAVI remain prevalent and impair survival in this generally old and comorbid-rich population. Due to changing aetiology of complications over time, antiplatelet and anticoagulant therapy after TAVI should be carefully balanced. Empirically, a dual antiplatelet strategy is generally used after TAVI for patients without an indication for oral anticoagulation (OAC; e. g. atrial fibrillation, mechanical mitral valve prosthesis), including aspirin and a thienopyridine. For patients on OAC, a combination of OAC and aspirin or thienopyridine is generally used. This review shows that current registries are unfit to directly compare antithrombotic regimens. Small exploring studies suggest that additional clopidogrel after TAVI only affects bleeding and not ischemic complications. However, these studies are lack in quality in terms of Cochrane criteria. Currently, three randomised controlled trials are recruiting to gather more knowledge about the effects of clopidogrel after TAVI.

scholarly journals TRANSCATHETER AORTIC VALVE IMPLANTATION PRESERVES MITRAL VALVE 3D GEOMETRY BETTER THAN STANDARD AVR

2010 ◽  
Vol 55 (10) ◽  
pp. A178.E1664
Author(s):  
mathieu vergnat ◽  
Joseph Bavaria ◽  
Benjamin M. Jackson ◽  
Albert T. Cheung ◽  
Stuart J. Weiss ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Transcatheter Aortic Valve ◽  
3D Geometry ◽  
Aortic Valve Implantation ◽  
Valve Implantation ◽  
Better Than
Sign in / Sign up

Export Citation Format

Share Document